Arthur G. Cook is Principal, ZS Associates.
Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is ...
LillyDirect exemplifies DTP as a demand-unlocking commercial channel rather than a compliance tactic, with executives ...
A cGMP-related CRL can delay approval despite substantial efficacy/safety evidence and often requires manufacturing remediation and reinspection rather than additional clinical trials. Phase III CARES ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...
Approval was supported by IRAKLIA Phase III non-inferiority data comparing on-body injector subcutaneous isatuximab to weight-based IV, both combined with pomalidomide and dexamethasone in R/R myeloma ...
The collaboration is positioned as a translational bridge for researchers and entrepreneurs, offering an end-to-end discovery ...
Extensive background and on-study uptake of TTR stabilizers likely diluted the observable marginal effect of a TTR-silencing agent, complicating attribution of benefit in the intent-to-treat primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results